Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Antirheumatic Agents/therapeutic use , Biological Products/therapeutic use , Coronavirus Infections , Pandemics , Pneumonia, Viral , Spondylarthritis , Betacoronavirus/isolation & purification , COVID-19 , Comorbidity , Coronavirus Infections/diagnosis , Coronavirus Infections/epidemiology , Coronavirus Infections/physiopathology , Female , France/epidemiology , Humans , Male , Medication Therapy Management/statistics & numerical data , Middle Aged , Pneumonia, Viral/diagnosis , Pneumonia, Viral/epidemiology , Pneumonia, Viral/physiopathology , SARS-CoV-2 , Spondylarthritis/diagnosis , Spondylarthritis/drug therapy , Spondylarthritis/epidemiology , Symptom Assessment , Symptom Flare UpSubject(s)
Antirheumatic Agents/therapeutic use , COVID-19 , Quarantine , Spondylarthritis/drug therapy , Adult , Female , Humans , Male , Middle Aged , Pandemics , Severity of Illness Index , Spondylarthritis/diagnosisABSTRACT
Spinal injections must be carried out adhering to very strict conditions. However, these procedures have almost come to be seen as everyday and may be practised under quite questionable conditions. The recent reports of new and extremely serious neurological complications have changed the attitudes of those making referrals as well as the attitudes of the interventional radiologists carrying out these procedures. The range of indications for transforaminal injections has shrunk in favour of epidural injections. Where the transforaminal approach is still used, the needle must be positioned extremely accurately. A prior radioopaque contrast medium injection is essential from a safety perspective. The transforaminal epidural injection via the transfacet approach looks to be a promising alternative that is strictly avascular.
Subject(s)
Injections, Spinal/methods , Pain/drug therapy , Spinal Nerve Roots , HumansABSTRACT
OBJECTIVES: Anti-tumour necrosis factor (TNF)-alpha therapies are considered category B drugs for pregnancy. Although sometimes prescribed to women of reproductive age, data in humans are limited with regard to safety for a developing fetus. The objectives of the present article are to report experience of anti-TNF-alpha use in pregnancy, and review the international literature. METHODS: Since 1999 the present authors have used anti-TNF-alpha (infliximab, etanercept, adalimumab) to treat patients with various chronic rheumatic conditions. All patients were prospectively followed during their treatment time and data were systematically collected. RESULTS: In a group of 442 patients treated with anti-TNF, three women with RA unexpectedly became pregnant One treated with etanercept chose a therapeutic termination at two and a half months, despite of any ultrasound anomaly, and satisfactory fetal growth. The other two patients (one with adalimumab exposure and one with etanercept exposure) delivered healthy infants. The following perinatal complications were observed: prematurity, neonatal jaundice, neonatal urinary Escherichia coli infection and adrenal congenital hyperplasia of probable hereditary origin. CONCLUSIONS: To date, there is no evidence that TNF-alpha antagonists are associated with embryo toxicity, teratogenicity or increased pregnancy loss. However, caution should be taken when anti-TNF agents are used during pregnancy, as human experience is still extremely limited, particularly in patients with rheumatic diseases among whom there are several alarming reports. The potential risk should be balanced against the known risks associated with DMARDs and steroid therapy. Large registries will be necessary before firm conclusions can be drawn.
Subject(s)
Antirheumatic Agents/adverse effects , Arthritis, Rheumatoid/drug therapy , Pregnancy Complications/drug therapy , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Adalimumab , Antibodies, Monoclonal/adverse effects , Antibodies, Monoclonal, Humanized , Arthritis, Juvenile/drug therapy , Arthritis, Psoriatic/drug therapy , Etanercept , Female , Humans , Immunoglobulin G/adverse effects , Infliximab , Maternal-Fetal Exchange , Pregnancy , Pregnancy Outcome , Prospective Studies , Receptors, Tumor Necrosis FactorABSTRACT
BACKGROUND: Patients treated with tumor necrosis factor-alpha (TNF-alpha) antagonists have an increased risk of infection, but infection due to Legionella pneumophila has rarely been described in patients receiving such therapy. METHODS: A registry involving 486 clinical departments in France was designed by a multidisciplinary group (Recherche Axée sur la Tolérance des Biothérapies [RATIO]) to collect data on opportunistic and severe infections occurring in patients treated with TNF-alpha antagonists. All cases are reported to RATIO in accordance with national health authorities and validated by infectious disease experts. The legionellosis rate among patients treated with TNF-alpha antagonists was compared with the rate in France overall. RESULTS: We report a 1-year consecutive series of 10 cases of L. pneumophila pneumonia in France in 2004, including 6 cases treated with adalimumab, 2 treated with etanercept, and 2 treated with infliximab. The median patient age was 51 years (range, 40-69 years). Eight patients were treated for rheumatoid arthritis, 1 was treated for cutaneous psoriasis, and 1 was treated for pyoderma gangrenosum. The median duration of TNF-alpha antagonist treatment at onset of infection was 38.5 weeks (range, 3-73 weeks). Eight patients were receiving concomitant treatment with corticosteroids, and 6 were receiving treatment with methotrexate. The relative risk of legionellosis when receiving treatment with a TNF-alpha antagonist, compared with the relative risk in France overall, was estimated to be between 16.5 and 21.0. We also report a second episode of confirmed legionellosis following the reintroduction of infliximab therapy. CONCLUSIONS: L. pneumophila pneumonia is a potentially severe but curable infection that might complicate anti-TNF-alpha therapy. In patients receiving anti-TNF-alpha who develop pneumonia, legionellosis should be systematically investigated, and first-line antibiotic therapy should be efficient against L. pneumophila.
Subject(s)
Legionella pneumophila , Legionnaires' Disease/drug therapy , Pneumonia/drug therapy , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Adalimumab , Adult , Aged , Antibodies, Monoclonal/therapeutic use , Antibodies, Monoclonal, Humanized , Communicable Diseases, Emerging/drug therapy , Etanercept , Female , Humans , Immunoglobulin G/therapeutic use , Infliximab , Male , Middle Aged , Receptors, Tumor Necrosis Factor/therapeutic useABSTRACT
OBJECTIVE: To assess the safety of anti-tumour necrosis factor (TNF)-alpha therapy in patients with rheumatoid arthritis (RA) or spondylarthropathies (SA) and concurrent chronic hepatitis B or C. METHODS: Records concerning 480 outpatients attending the Rheumatology Department of the University Hospital of Nice (France) for RA or SA were retrospectively reviewed for the duration of disease, treatment, serological status and biological data. RESULTS: Six relevant cases were identified: two of RA with chronic hepatitis B; one of SA with chronic hepatitis B and three of RA with chronic hepatitis C. Five patients had received etanercept and one infliximab; two had been given adalimumab after an unsuccessful trial of etanercept. Patients with concurrent chronic hepatitis B were also given lamivudine. In none of the cases had changes in serum aminotransferases or viral load been reported. CONCLUSION: The use of anti-TNF-alpha therapy (plus lamivudine in the presence of concurrent underlying hepatitis B viral infection) appeared to be safe in that it had no effect on serum aminotransferases and/or viral load. However, repeated monitoring is necessary throughout the treatment period.
Subject(s)
Antirheumatic Agents/therapeutic use , Arthritis, Rheumatoid/drug therapy , Arthritis, Rheumatoid/virology , Hepatitis, Chronic/complications , Hepatitis, Chronic/drug therapy , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Adalimumab , Antibodies, Monoclonal/therapeutic use , Antibodies, Monoclonal, Humanized , Antiviral Agents/therapeutic use , Drug Therapy, Combination , Etanercept , Female , Hepatitis B, Chronic/complications , Hepatitis B, Chronic/drug therapy , Hepatitis C, Chronic/complications , Hepatitis C, Chronic/drug therapy , Humans , Immunoglobulin G/therapeutic use , Infliximab , Lamivudine/therapeutic use , Male , Middle Aged , Receptors, Tumor Necrosis Factor/therapeutic use , Retrospective Studies , Spondylarthropathies/drug therapy , Spondylarthropathies/virology , Transaminases/blood , Treatment Outcome , Viral LoadABSTRACT
We describe a case of IgD myeloma with amyloid and plasmocytic pleural localisations. At the onset of the disease it mimicked rheumatoid arthritis, which can be the first presentation of both AL amyloidosis and multiple myeloma. Pleural effusion can happen first in IgD myeloma, but our observation is of interest in that it confirms the very rare possibility of pleural amyloid and plasmocytic localisations devoid of pleural effusion.
Subject(s)
Amyloidosis/complications , Immunoglobulin D/blood , Multiple Myeloma/complications , Pleural Diseases/complications , Amyloidosis/blood , Amyloidosis/diagnosis , Biopsy , Diagnosis, Differential , Female , Follow-Up Studies , Humans , Immunoelectrophoresis , Magnetic Resonance Imaging , Middle Aged , Multiple Myeloma/blood , Multiple Myeloma/diagnosis , Pleura/diagnostic imaging , Pleura/pathology , Pleural Diseases/blood , Pleural Diseases/diagnosis , Tomography, X-Ray ComputedSubject(s)
Antibodies, Monoclonal/therapeutic use , Antirheumatic Agents/therapeutic use , Arthritis, Rheumatoid/drug therapy , Adalimumab , Aged , Antibodies, Monoclonal, Humanized , Etanercept , Female , Humans , Immunoglobulin G/therapeutic use , Infliximab , Male , Middle Aged , Receptors, Tumor Necrosis Factor/therapeutic use , Treatment FailureSubject(s)
Antibodies, Monoclonal/adverse effects , Antirheumatic Agents/adverse effects , Legionellosis/chemically induced , Aged , Antibodies, Monoclonal/therapeutic use , Antirheumatic Agents/therapeutic use , Arthritis, Rheumatoid/drug therapy , Female , Humans , Infliximab , Legionellosis/pathologyABSTRACT
OBJECTIVE: Patients with severe rheumatoid arthritis and resistant to at least three DMARDS can benefit from anti-TNFalpha (tumor necrosis factor) therapy. In some patients, because of inefficacy or adverse events, treatment with one of the two available TNFalpha drugs (etanercept and infliximab) must be stopped. In this study, we explored the results in efficacy and tolerance of switching from one anti-TNFalpha to the other. PATIENTS: Between August 1999 and January 2002, we administered one of the two anti TNFalpha drugs to 131 patients: 67 patients received infiximab and 64 etanercept. RESULTS: Among the 67 patients treated with infliximab, 17 patients had to stop treatment. In 8 of them (4 allergies, 2 infections and 2 non responders) the switch from infliximab to etanercept was beneficial for 5 patients, 2 patients did not respond and 1 patient withdrew for personal reasons. Among the 64 patients treated with etanercept, 13 had to stop treatment. In 6 of them (2 adverse events, 4 failures) the switch from etanercept to infliximab was beneficial for 3 patients, 2 did not respond and 1 withdrew because of adverse events. CONCLUSION: In all, 14 patients with severe rheumatoid arthritis and treated by one of the two TNFalpha drugs (and in whom treatment was stopped because of adverse events or inefficacy) benefited from the switch to the other anti- TNFalpha, with excellent response in 8 out of 14 patients.
Subject(s)
Antibodies, Monoclonal/therapeutic use , Antirheumatic Agents/therapeutic use , Arthritis, Rheumatoid/drug therapy , Immunoglobulin G/therapeutic use , Receptors, Tumor Necrosis Factor/therapeutic use , Aged , Antibodies, Monoclonal/administration & dosage , Antibodies, Monoclonal/adverse effects , Antirheumatic Agents/administration & dosage , Antirheumatic Agents/adverse effects , Drug Therapy, Combination , Etanercept , Female , Humans , Immunoglobulin G/administration & dosage , Immunoglobulin G/adverse effects , Immunosuppressive Agents/administration & dosage , Immunosuppressive Agents/therapeutic use , Infliximab , Male , Methotrexate/administration & dosage , Methotrexate/therapeutic use , Middle Aged , Receptors, Tumor Necrosis Factor/administration & dosage , Time FactorsABSTRACT
We report the case of a 46-year-old patient in whom ulcerative colitis had been diagnosed three years ago. He was admitted to the hospital for swelling of the nose. Clinical course and complementary exams led us to diagnose atrophic polychondritis. Twelve cases of such an association have been published so far.
Subject(s)
Colitis, Ulcerative/complications , Polychondritis, Relapsing/diagnosis , Humans , Male , Middle Aged , Nose , Polychondritis, Relapsing/complications , Polychondritis, Relapsing/drug therapy , Prednisolone/therapeutic use , TechnetiumABSTRACT
BACKGROUND: Sympathetic reflex dystrophy is an uncommon cause of pelvic pain not to be overlooked in pregnant women. CASE REPORT: At 8 months pregnancy, a 27-year-old woman complained of invalidating pain of the left hip. Magnetic resonance imaging of the pelvis performed the day after delivery evidenced a non-displaced fracture of the femoral neck and a typical aspect of sympathetic reflex dystrophy. DISCUSSION: The true frequency of sympathetic reflex dystrophy during pregnancy is probably underestimated. Approximately one hundred cases have been reported. The hip joint is involved in 9 out of 10 cases. Such localizations are uncommon outside pregnancy, accounting for 14 to 17% of all cases.
Subject(s)
Femoral Neck Fractures/etiology , Pregnancy Complications/diagnosis , Reflex Sympathetic Dystrophy/complications , Adult , Female , Femoral Neck Fractures/diagnosis , Humans , Magnetic Resonance Imaging , Pregnancy , Pregnancy Trimester, Third , Reflex Sympathetic Dystrophy/diagnosisABSTRACT
Sacral insufficiency fractures are not rare. They are well known in female patients over age 50 with osteopenia. One case occurring in a young pregnant woman is described. We did not find another case in the literature.
Subject(s)
Bone Diseases, Metabolic/complications , Fractures, Spontaneous/etiology , Pregnancy Complications , Sacrum , Adult , Female , Humans , Low Back Pain/etiology , Pregnancy , Sciatica/etiologyABSTRACT
Reactive arthritis induced by Strongyloides is exceedingly rare. A case in a 53-year-old man from the Guadeloupe (French Antilles) is reported. The outcome was rapidly favorable under thiabendazole therapy. The cycle of Strongyloides is reviewed, and the contribution of parasites to reactive arthritis in patients with genetic risk factors is discussed. Establishing the correct diagnosis is sometimes difficult but is essential in order to avoid inappropriate administration of corticosteroids that can lead to fatal, multivisceral dissemination of the parasite, particularly in patients with strongyloidiasis.